Buzz Stocks: AbbVie, Achillion, Caesars Entertainment

Today's stocks to watch in the news include ABBV, ACHN, and CZR

Dec 22, 2014 at 9:01 AM
facebook X logo linkedin


After concluding their best week in years, U.S. stocks are set to kick off a holiday-shortened week on a merry note. Among the equities in focus are drugmakers AbbVie Inc (NYSE:ABBV) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), as well as casino concern Caesars Entertainment Corp (NASDAQ:CZR).

  • ABBV is pointed 3% higher ahead of the bell, after inking an exclusive deal with Express Scripts Holding Company (NASDAQ:ESRX). Specifically, ESRX said its biggest plan will cover only ABBV's newly approved Viekira Pak hepatitis C treatment, and will exclude similar treatments from Gilead Sciences, Inc. (NASDAQ:GILD), among others. As such, AbbVie Inc shares could explore record-high territory north of $71, extending their year-to-date surplus of more than 28%. What's more, an unwinding of pessimism in the options pits could add fuel to the equity's fire. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the equity's 10-day put/call volume ratio of 0.78 stands just 6 percentage points from an annual bearish peak. On Friday, ABBV settled at $67.71.

  • Meanwhile, fellow biotech concern ACHN is set to soar 11% out of the gate, thanks to encouraging data on its own hepatitis C treatment. Achillion Pharmaceuticals, Inc. has outperformed the S&P 500 Index (SPX) by nearly 22 percentage points during the past three months, landing at $14.21 on Friday. The stock has more than quadrupled in value in 2014, so it's no surprise to find nine out of 10 analysts offer up "strong buy" opinions. However, the consensus 12-month price target of $13.22 stands at a discount to ACHN's current perch, suggesting price-target hikes could be on the horizon.

  • Finally, CZR was temporarily halted in pre-market trading, upon announcing an all-stock deal to buy Caesars Acquisition Company (NASDAQ:CACQ). The shares of CZR have since resumed electronic trading, and are headed for a 24% jump at the opening bell. Caesars Entertainment Corp has struggled in 2014, surrendering 37.4% to finish at $13.49 on Friday. In light of today's merger news, a mass exodus of bears could propel CZR even higher. Short interest accounts for 42% of the stock's total available float, representing 13 sessions' worth of pent-up buying demand, at CZR's average pace of trading. Plus, not one of the four analysts following the shares deems them worthy of a "buy" endorsement.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI